A multicentre, open-label, extension study, evaluating the safety and tolerability and the efficacy of ADV7103 at long term in distal renal tubular acidosis patients.

Trial Profile

A multicentre, open-label, extension study, evaluating the safety and tolerability and the efficacy of ADV7103 at long term in distal renal tubular acidosis patients.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs Potassium bicarbonate/potassium citrate (Primary)
  • Indications Metabolic acidosis; Renal tubular acidosis
  • Focus Adverse reactions; Registrational
  • Sponsors Advicenne
  • Most Recent Events

    • 06 Nov 2017 According to an Advicenne media release, positive data will form basis for application seeking market authorization of ADV7103 to the European Medicines Agency in Europe for dRTA expected in 2018.
    • 06 Nov 2017 Preliminary results of the 6-month follow up study presented at the American Society of Nephrology (ASN) meeting 2017, according to an Advicenne media release.
    • 06 Nov 2017 Preliminary results of the 6-month follow up study presented in an Advicenne media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top